Abstract: Provided herein are cytokine muteins and cytokine prodrugs and methods of making and using thereof.

Abstract: The present application relates to novel chimeric molecules or prodrugs of IL-12. Specifically, disclosed provides a chimeric molecule, which comprises an IL-12 p40 subunit (p40), an IL-12 p35 subunit (p35), and which may further comprises a masking moiety (MM), and/or a carrier (C). Further included in the present application are methods of making and using the novel chimeric molecules or prodrugs.

Abstract: The present disclosure relates to fusion molecules and chimeric molecules which comprise two components: an Ang-2 antagonist peptide linked to a VEGF-binding moiety. Further disclosed are methods of using said chimeric molecules to treat a patient cancer, proliferative retinopathy, neovascular glaucoma, macular edema, wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), or diabetic retinopathy (DR).

Abstract: The present disclosure relates to chimeric molecules which are fusion proteins comprising two components: an Ang-2 binding peptide linked to either a VEGF antibody or a VEGF receptor-Fc fusion protein. The Ang2 peptide, VEGF antibody, and VEGF receptor-Fc fusion proteins are each defined below with reference to percent identity to a reference sequence. The chimeric molecule is a fusion protein, dual antagonist of Ang2 and VEGF for treatment of cancers, proliferative retinopathies, neovascular glaucoma, macular edema, AMD, and rheumatoid arthritis.

Abstract: The present disclosure relates to prodrugs or chimeric molecules which comprise a carrier moiety, a cytokine moiety selected from an IL-10 agonist polypeptide and a TGF-? agonist polypeptide, and a masking moiety that binds to said cytokine moiety and inhibits its biological activity. Further included in the present disclosure are methods of making and using the novel prodrugs or chimeric molecules.

Abstract: Provided herein are interferon prodrugs and methods of making and using thereof for stimulating the immune system, or treating cancer or an infectious disease.

Abstract: Provided herein are IL-15 cytokine prodrugs and methods of making and using thereof.

Abstract: Provided herein are IL-15 cytokine prodrugs and methods of making and using thereof.

Abstract: Described and provided herein are novel antibodies for Claudin 18.2. Also described and provided are pharmaceutical compositions of the antibodies and methods of use for the treatment of cancer.

Abstract: The present disclosure relates to chimeric molecules which are fusion proteins comprising two components: an Ang-2 binding peptide linked to either a VEGF antibody or a VEGF receptor-Fc fusion protein. The Ang2 peptide, VEGF antibody, and VEGF receptor-Fc fusion proteins are each defined below with reference to percent identity to a reference sequence. The chimeric molecule is a fusion protein, dual antagonist of Ang2 and VEGF for treatment of cancers, proliferative retinopathies, neovascular glaucoma, macular edema, AMD, and rheumatoid arthritis.

Abstract: The present specification discloses a pharmaceutical composition or stable aqueous formulations for erythropoietin receptor agonists, compositions and medicaments comprising such erythropoietin receptor agonists, and methods and uses of erythropoietin receptor agonists and compositions. The present specification further discloses medicaments for treating an anemia in non-human mammals such as cats.

Abstract: Provided herein are prodrugs and methods of making and using thereof for stimulating the immune system, or treating cancer, autoimmune or an infectious disease.

Abstract: Described and provided herein are novel antibodies for Claudin 18.2. Also described and provided are pharmaceutical compositions of the antibodies and methods of use for the treatment of cancer.

Abstract: The present application relates to novel prodrugs of IL-12. Further included in the present application are methods of making and using the novel prodrugs.

Abstract: The present disclosure provides novel isolated IL-2 fusion molecules that preferentially activate regulatory T cells (Treg) in vitro and in vivo. Further included are methods of making and using said novel fusion molecules to treat inflammatory and autoimmune diseases.

Abstract: Provided herein are IL-21 prodrugs and methods of making and using thereof for stimulating the immune system, or treating cancer or an infectious disease.

Abstract: The present disclosure relates to fusion molecules and chimeric molecules which comprise two components: an Ang-2 antagonist peptide linked to a VEGF-binding moiety. Further disclosed are methods of using said chimeric molecules to treat a patient cancer, proliferative retinopathy, neovascular glaucoma, macular edema, wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), or diabetic retinopathy (DR).

Abstract: Provided herein are cytokine muteins and cytokine prodrugs and methods of making and using thereof.

Abstract: The present disclosure relates to fusion molecules and chimeric molecules which comprise two components: an Ang-2 antagonist peptide linked to a VEGF-binding moiety. Further disclosed are methods of using said chimeric molecules to treat a patient cancer, proliferative retinopathy, neovascular glaucoma, macular edema, wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), or diabetic retinopathy (DR).

Abstract: Provided herein are IL-21 prodrugs and methods of making and using thereof for stimulating the immune system, or treating cancer or an infectious disease.